Health & Fitness
Health and Fitness
Health and Fitness
Mon, March 4, 2013Sun, March 3, 2013Sat, March 2, 2013Fri, March 1, 2013Thu, February 28, 2013Wed, February 27, 2013Tue, February 26, 2013Mon, February 25, 2013Sun, February 24, 2013Sat, February 23, 2013Fri, February 22, 2013Thu, February 21, 2013Wed, February 20, 2013Tue, February 19, 2013Mon, February 18, 2013Sun, February 17, 2013Fri, February 15, 2013Thu, February 14, 2013Wed, February 13, 2013Tue, February 12, 2013Mon, February 11, 2013Sun, February 10, 2013Fri, February 8, 2013Transcept Pharmaceuticals to Report Fourth Quarter and Full Year 2012 Financial Results and Host Conference Call on February 27
Published in Health and Fitness on Thursday, February 21st 2013 at 4:01 GMT by Market Wire
Transcept Pharmaceuticals to Report Fourth Quarter and Full Year 2012 Financial... -- POINT RICHMOND, Calif., Feb. 21, 2013 /PRNewswire/ --
POINT RICHMOND, Calif., Feb. 21, 2013 /PRNewswire/ -- Transcept Pharmaceuticals, Inc. (Nasdaq: [ TSPT ]), a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company will host a conference call on Wednesday, February 27, 2013, at 4:30 p.m. Eastern Time to discuss its fourth quarter and full year 2012 financial results. The conference call will follow the release of the Transcept fourth quarter and full year 2012 financial results after the close of market that day.
Conference Call Information | |
Date: Wednesday, February 27, 2013 | |
Time: 4:30 p.m. ET | |
Dial-in (U.S.): 877-638-4558 | |
Dial-in (International): 914-495-8537 | |
A simultaneous webcast of the conference call will be available on the Investors section of the Transcept website at [ www.transcept.com ]. A replay of this webcast will be available on the website shortly after the conclusion of the call through March 31, 2013.
About Transcept
Transcept Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo® (zolpidem tartrate) sublingual tablet C-IV is the first FDA approved Transcept product. Purdue Pharma holds commercialization and development rights for Intermezzo in the United States. For further information about Transcept, please visit [ www.transcept.com ]. For information about Intermezzo, please visit [ www.MyIntermezzo.com ].
Contact:
Transcept Pharmaceuticals, Inc.
Greg Mann
Sr. Director, Corporate Communications
(510) 215-3567
[ gmann@transcept.com ]
SOURCE Transcept Pharmaceuticals, Inc.
RELATED LINKS
[ http://www.transcept.com ]
[ http://www.myintermezzo.com ]
